Streetwise Articles



2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market
Source: The Life Sciences Report(4/19/17)
The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.
More >


String of Positive Trial Results Boosts RepliCel's Profile
Source: The Life Sciences Report(4/12/17)
Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss. More >


Steve Palmer

Five Companies with Favorable Risk/Reward Profiles from the AlphaNorth Capital Conference
Source: The Life Sciences Report(4/12/17)
The 4th annual AlphaNorth Capital Conference brought together over 40 emerging growth companies with top investors. In this interview with Streetwise Reports, Steve Palmer, founder and president of AlphaNorth Asset Management and a co-organizer of the conference, discusses a diverse group of companies that were selected to attend the conference, including three biotech companies. More >


RXi Pharmaceuticals Receives Japanese Patent for RNAi Platform
Source: The Life Sciences Report(4/12/17)
With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform. More >


Eden Rahim

Four Biotech Mid-Caps Fund Manager Eden Rahim Believes Have Favorable Catalysts
Source: The Life Sciences Report(4/5/17)
Biotech may be the last great bastion of stock picking, posits Eden Rahim, who manages the Toronto-based Next Edge Bio-Tech Plus Fund. The fund is up 40% in the last 12 months. In this interview with The Life Sciences Report, Rahim provides his view of the sector and profiles four companies he believes may have great upside. More >


VistaGen Therapeutics Advances New-Generation Antidepressant Approved by European Patent Office
Source: The Life Sciences Report(4/5/17)
In a milestone for South San Francisco-based VistaGen Therapeutics, the European Patent Office (EPO) has issued a Notice of Intention to grant the company patents for its antidepressant prodrug, AV-101. More >


Cash-Rich Zynerba's Synthetic Cannabinoid Product Line Ready to Rumble
Source: The Life Sciences Report(4/5/17)
Zynerba Pharmaceuticals specializes in developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Devon, Pennsylvania-based company's Q4/16 financial results disclose a substantial cash kitty of ~$78M available to fund its pipeline of medical marijuana products, ZYN001 and ZYN002. More >


3D Signatures' TeloView Can Diagnose Alzheimer's with Cheek Swab
Source: The Life Sciences Report(3/30/17)
With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form. More >


James Brown

Many Paths to Success with DURECT's Pipeline
Source: Dr. James Brown for The Life Sciences Report(3/29/17)
DURECT has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the potentially groundbreaking epigenetic regulator DUR-928, POSIMIR's late-stage testing for postoperative pain and an abuse-deterrent oral technology. More >


Therapix IPO on NASDAQ Could Catapult It into the Big Leagues
Source: The Life Sciences Report(3/21/17)
Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs. More >


RepliCel's Phase 1 Trial for Hair Loss Completed Successfully
Source: The Life Sciences Report(3/16/17)
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. More >


3D Signatures' Disruptive Technology Moving Ahead for Prostate Cancer and Hodgkin's Lymphoma
Source: The Life Sciences Report(3/8/17)
3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests. More >


Major Funds Betting On Trump Sector
Source: Tom Beck for The Life Sciences Report(2/25/17)
Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.S., says Tom Beck, editor of Portfolio Wealth Global. More >


Lior Gantz

Buckle Up: Inflation at 58-Month High
Source: Lior Gantz for The Gold Report(2/23/17)
The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena. More >


RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
Source: The Life Sciences Report(2/22/17)
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. More >


Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth
Source: The Life Sciences Report(2/22/17)
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice. More >


0

Investing in Life Sciences Under the Trump Presidency
Source: Kristin McFarland for The Life Sciences Report(2/16/17)
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. More >


Regeneus Hits the Fast Track with Major Japanese Partnership
Source: The Life Sciences Report(2/8/17)
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. More >


Bob Moriarty

Luminor Drives the Scout DS Forward
Source: Bob Moriarty for The Life Sciences Report(2/6/17)
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. More >


The Future of Cannabis Investing
Source: Tom Beck for Streetwise Reports(2/3/17)
The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global. More >


ContraVir's Hep B Drug Could Be a Game Changer
Source: The Life Sciences Report(2/1/17)
In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company. More >


Colin Lee Novick

Companies Flocking to Japan for Biotech Deals
Source: Colin Lee Novick for The Life Sciences Report(2/1/17)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. More >


Inovio's Zika Vaccine Generates Robust Immune Responses
Source: The Life Sciences Report(1/25/17)
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. More >


2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Source: The Life Sciences Report(1/18/17)
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. More >


Jason Napodano

Time to Go Long on BrainStorm Cell Therapeutics?
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report(1/16/17)
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. More >


Showing Results: 1 to 25 of 366 Next